By founding and funding the Institute for Clinical and Economic Review (ICER), insurance companies have found a new way to justify excluding live-saving drugs from formularies. ICER does a version of something called “comparative effectiveness” to determine whether, across the population, the drugs are worth the cost compared to other treatments. It releases the findings around the same time drugs come to market, just in time for insurance companies who, not coincidentally, serve on ICER’s governing board, to justify excluding FDA approved drugs from the formulary based, in part, on ICER’s “independent” math. Read more here.
Last Updated on May 12, 2020 by Aimed Alliance
